Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer

TitleOncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer
Authors
Keywordscervical cancer
cervical intraepithelial neoplasia
diagnostic biomarker
human papillomavirus
microRNA
sensitivity and specificity
Issue Date2018
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/wps/product/cws_home/709916
Citation
Molecular Oncology, 2018 How to Cite?
AbstractCervical cancer is one of the leading causes of cancer death in women globally, despite the widespread use of cytology/human papillomavirus (HPV) screening. In the present study, we aimed to identify the potential role of microRNA (miRNA) as a diagnostic biomarker in the detection of cervical pre-malignant lesions and cancer. In total, we recruited 582 patients with cervical diseases and 145 control individuals. The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer and pre-malignant lesions compared to normal cervical samples, indicating that they are oncogenic miRNAs. Receiver operating characteristic curve analysis showed that these six miRNAs can be used to distinguish patients with cervical pre-malignant lesions or cancer from normal individuals and they also had a good predictive performance, particularly in cervical lesions. Combined use of these six miRNAs further enhanced the diagnostic accuracy over any single miRNA marker, with an area under the curve of 0.998, 0.996 and 0.959, a diagnostic sensitivity of 97.9%, 97.2% and 91.4%, and a specificity of 98.6%, 96.6% and 87.6% for low-grade lesions, high-grade lesions and cancer, respectively. This six oncogenic miRNA signature may be suitable for use as diagnostic marker for cervical pre-malignant lesions and cancer in the near future.
Persistent Identifierhttp://hdl.handle.net/10722/260344
ISSN
2015 Impact Factor: 5.367
2015 SCImago Journal Rankings: 2.857

 

DC FieldValueLanguage
dc.contributor.authorLiu, S-
dc.contributor.authorChan, KKL-
dc.contributor.authorChu, KH-
dc.contributor.authorWei, N-
dc.contributor.authorLau, SK-
dc.contributor.authorNgu, SF-
dc.contributor.authorChu, MYM-
dc.contributor.authorTse, KY-
dc.contributor.authorIp, PCP-
dc.contributor.authorNg, KO-
dc.contributor.authorCheung, ANY-
dc.contributor.authorNgan, HYS-
dc.date.accessioned2018-09-14T08:40:07Z-
dc.date.available2018-09-14T08:40:07Z-
dc.date.issued2018-
dc.identifier.citationMolecular Oncology, 2018-
dc.identifier.issn1574-7891-
dc.identifier.urihttp://hdl.handle.net/10722/260344-
dc.description.abstractCervical cancer is one of the leading causes of cancer death in women globally, despite the widespread use of cytology/human papillomavirus (HPV) screening. In the present study, we aimed to identify the potential role of microRNA (miRNA) as a diagnostic biomarker in the detection of cervical pre-malignant lesions and cancer. In total, we recruited 582 patients with cervical diseases and 145 control individuals. The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer and pre-malignant lesions compared to normal cervical samples, indicating that they are oncogenic miRNAs. Receiver operating characteristic curve analysis showed that these six miRNAs can be used to distinguish patients with cervical pre-malignant lesions or cancer from normal individuals and they also had a good predictive performance, particularly in cervical lesions. Combined use of these six miRNAs further enhanced the diagnostic accuracy over any single miRNA marker, with an area under the curve of 0.998, 0.996 and 0.959, a diagnostic sensitivity of 97.9%, 97.2% and 91.4%, and a specificity of 98.6%, 96.6% and 87.6% for low-grade lesions, high-grade lesions and cancer, respectively. This six oncogenic miRNA signature may be suitable for use as diagnostic marker for cervical pre-malignant lesions and cancer in the near future.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/wps/product/cws_home/709916-
dc.relation.ispartofMolecular Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcervical cancer-
dc.subjectcervical intraepithelial neoplasia-
dc.subjectdiagnostic biomarker-
dc.subjecthuman papillomavirus-
dc.subjectmicroRNA-
dc.subjectsensitivity and specificity-
dc.titleOncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer-
dc.typeArticle-
dc.identifier.emailLiu, S: stephasl@hku.hk-
dc.identifier.emailChan, KKL: kklchan@hkucc.hku.hk-
dc.identifier.emailChu, KH: khchu12@HKUCC-COM.hku.hk-
dc.identifier.emailWei, N: tinawei@hku.hk-
dc.identifier.emailLau, SK: lsk382@hkucc.hku.hk-
dc.identifier.emailNgu, SF: ngusiewf@hku.hk-
dc.identifier.emailChu, MYM: chumy@hku.hk-
dc.identifier.emailTse, KY: tseky@hku.hk-
dc.identifier.emailIp, PCP: philipip@hku.hk-
dc.identifier.emailCheung, ANY: anycheun@hkucc.hku.hk-
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityLiu, S=rp00372-
dc.identifier.authorityChan, KKL=rp00499-
dc.identifier.authorityNgu, SF=rp01367-
dc.identifier.authorityTse, KY=rp02391-
dc.identifier.authorityIp, PCP=rp01890-
dc.identifier.authorityCheung, ANY=rp00542-
dc.identifier.authorityNgan, HYS=rp00346-
dc.description.naturepublished_or_final_version-
dc.identifier.pmid30221475-
dc.identifier.hkuros291315-
dc.identifier.hkuros294143-
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats